Quantcast

Latest Methotrexate Stories

2009-10-19 07:02:00

PHILADELPHIA, Oct. 19 /PRNewswire/ -- Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA). Radiographic analyses showed that treatment with SIMPONI resulted in a statistically significant reduction in change from baseline in...

2009-10-14 11:59:42

Medications that block folic acid are associated with increased abnormalities Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynecologists who examined birth and abortion data collected in Israel between 1998 and 2007. The study drew...

2009-09-28 13:34:00

MENLO PARK, Calif. and NEW YORK and BIRMINGHAM, Ala., Sept. 28 /PRNewswire/ -- The U.S. Food & Drug Administration has announced the approval of pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Research on drugs of this class began in the 1950s at SRI International. A subsequent scientific collaboration among SRI International, Memorial Sloan-Kettering Cancer Center, and Southern Research Institute led to clinical trials on related compounds...

2009-09-25 17:24:00

MENLO PARK, Calif., NEW YORK and BIRMINGHAM, Ala., Sept. 25 /PRNewswire/ -- The U.S. Food & Drug Administration has announced the approval of pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Research on drugs of this class began in the 1950s at SRI International. A subsequent scientific collaboration among SRI International, Memorial Sloan-Kettering Cancer Center, and Southern Research Institute led to clinical trials on related compounds...

2009-09-22 02:00:00

MAIDENHEAD, England, September 22 /PRNewswire/ -- - 26 Men and Women With RA From Across Europe Honoured as They Share Their Inspirational Stories Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening to recognise the daily challenges, hopes and achievements of people living with rheumatoid arthritis (RA). To view the Multimedia News Release, please click: http://www.prnewswire.com/mnr/wyeth/40154/...

2009-08-04 05:30:00

THE WOODLANDS, Texas, Aug. 4 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX2931 in patients with rheumatoid arthritis. LX2931 is an orally-delivered, small molecule drug candidate that has recently completed Phase 1 testing in normal volunteers. Lexicon also successfully completed a...

2009-07-07 08:00:00

DALLAS, July 7 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today new preclinical data demonstrating that thiarabine shows remarkable efficacy in the prevention and treatment of rheumatoid arthritis (RA). In a well-established animal model for RA, an exceptional restoration of joint structure was observed in the studies, which were conducted at Wayne State University School of Medicine and at Southern Research Institute. As a therapeutic...

849482a7e26cddb48889342250795f701
2009-06-17 11:40:00

Researchers have found that patients dealing with the early stages of rheumatoid arthritis could benefit from a drug currently reserved for people in the advanced stages of the disease.Researchers studied 755 patients using rituximab, also known as MabThera, alongside the traditional early RA drug, methotrexate.The combination of both drugs resulted in fewer symptoms and slower damage progress, researchers reported at the European League Against Rheumatism (EULAR) conference."At the moment we...

2009-06-11 09:24:31

Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved inactive disease status, according to a new study presented today presented today at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.Effective treatment options are available to...

2009-06-09 17:01:00

- Additional data reinforce long-term efficacy of ACTEMRA across a broad range of rheumatoid arthritis patient populations - NUTLEY, N.J., June 9 /PRNewswire/ -- One-year data from the two-year Phase III LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with ACTEMRA(R) (tocilizumab), a novel interleukin-6 (IL-6) receptor inhibitor, in combination with methotrexate, experienced...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related